{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:36:58Z","timestamp":1770817018651,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Drug challenge is the gold standard for identifying causative agents of drug allergies. Although clinical guidelines have recently been published, they do not recommend neuromuscular blocking agent (NMBA) drug challenges. NMBA challenges are rendered difficult by the lack of homogeneity of routine allergy work-ups and the necessity of a specialised setting. Several scenarios support NMBA challenges, such as an ambiguous allergy work-up, a high suspicion of a false-positive skin test or identification of a well tolerated alternative NMBA strategy. Furthermore, routine allergy work-ups may not recognise non-IgE mechanisms, such as IgG or MRGPRX2, whereas drug challenges may reveal them. Finally, if the culprit NMBA is not identified, subsequent anaesthesia regimens will be challenging to implement, resulting in increased risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE(S)<\/jats:title>\n            <jats:p>This literature review discusses the indications, strategies, doses, monitoring methods, limitations, and unresolved issues related to drug challenges for NMBAs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN<\/jats:title>\n            <jats:p>The literature review included randomised controlled trials, observational studies, reviews, case reports, series, and comments on humans.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SOURCES<\/jats:title>\n            <jats:p>Studies were retrieved from databases (PubMed) and electronic libraries (OVID, EMBASE, Scopus, etc.).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>ELIGIBILITY CRITERIA<\/jats:title>\n            <jats:p>All studies that referred to the NMBA challenge were included without publication date limitations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>NMBA challenge may be considered in NMBA anaphylaxis patients with inconclusive or ambivalent IgE diagnostic work-up under controlled conditions (presence of anaesthetists and allergists with continuous monitoring in a secured environment). To illustrate its utility, a case report of a double NMBA challenge in a patient with NMBA cross-reactivity is presented, along with biological explorations to detect subclinical cellular activation, a novel aspect of this procedure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Drug challenges could be implemented during the NMBA allergy work-up under strict safety conditions at specialised centres with close collaboration between anaesthetists and allergists. This could decrease uncertainty and contribute to defining a safer strategy for subsequent anaesthetic drug regimens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/eja.0000000000002033","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T08:10:22Z","timestamp":1719303022000},"page":"722-727","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Neuromuscular blocking agent drug challenge: a literature review and protocol proposal with biological evaluation"],"prefix":"10.1097","volume":"41","author":[{"given":"Aur\u00e9lie","family":"Gouel-Ch\u00e9ron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Neukirch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chollet-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Plaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Longrois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Nicaise-Roland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"de Chaisemartin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"R1-20250801","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1398-9995.2007.01347.x","article-title":"Anaphylaxis during anaesthesia: diagnostic approach","volume":"62","author":"Ebo","year":"2007","journal-title":"Allergy"},{"key":"R2-20250801","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: A 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R3-20250801","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1034\/j.1398-9995.2003.00279.x","article-title":"Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations","volume":"58","author":"Aberer","year":"2003","journal-title":"Allergy"},{"key":"R4-20250801","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.bja.2019.03.018","article-title":"The use of drug provocation testing in the investigation of suspected immediate perioperative allergic reactions: current status","volume":"123","author":"Garvey","year":"2019","journal-title":"Br J Anaesth"},{"key":"R5-20250801","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2500\/aap.2021.42.200091","article-title":"Skin testing and drug challenge in the evaluation of drug hypersensitivity reactions","volume":"42","author":"Wolfson","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"R6-20250801","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.bja.2019.04.044","article-title":"Management of suspected immediate perioperative allergic reactions: an international overview and consensus recommendations","volume":"123","author":"Garvey","year":"2019","journal-title":"Br J Anaesth"},{"key":"R7-20250801","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40521-016-0078-0","article-title":"Perioperative hypersensitivity reactions: diagnosis, treatment and evaluation","volume":"3","author":"Garvey","year":"2016","journal-title":"Curr Treat Options Allergy"},{"key":"R8-20250801","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2222.2008.03155.x","article-title":"BSACI guidelines for the management of drug allergy","volume":"39","author":"Mirakian","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"R9-20250801","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0021-8707(61)90016-8","article-title":"The incidence of positive intradermal reactions and the demonstration of skin sensitizing antibody to extracts of ragweed and dust in humans without history of rhinitis or asthma","volume":"32","author":"Lindblad","year":"1961","journal-title":"J Allergy"},{"key":"R10-20250801","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.lpm.2016.02.024","article-title":"Epidemiology of perioperative anaphylaxis","volume":"45","author":"Mertes","year":"2016","journal-title":"La Presse M\u00e9dicale"},{"key":"R11-20250801","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaci.2011.03.003","article-title":"Anaphylaxis during anesthesia in France: an 8-year national survey","volume":"128","author":"Mertes","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R12-20250801","doi-asserted-by":"crossref","first-page":"216","DOI":"10.18176\/jiaci.0236","article-title":"Practical guidelines for perioperative hypersensitivity reactions","volume":"28","author":"Laguna","year":"2018","journal-title":"J Invest Allergol Clin Immunol"},{"key":"R13-20250801","doi-asserted-by":"crossref","first-page":"eaat1479","DOI":"10.1126\/scitranslmed.aat1479","article-title":"An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis","volume":"11","author":"J\u00f6nsson","year":"2019","journal-title":"Sci Transl Med"},{"key":"R14-20250801","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.bja.2022.07.039","article-title":"Drug provocation tests with hypnotics, opioids, and neuromuscular blocking agents in the diagnosis of suspected perioperative hypersensitivity","volume":"129","author":"Poorten M-LM van der","year":"2022","journal-title":"Br J Anaesth"},{"key":"R15-20250801","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(77)91953-5","article-title":"Incidence and severity of anaphylactoid reactions to colloid volume substitutes","volume":"309","author":"Ring","year":"1977","journal-title":"Lancet"},{"key":"R16-20250801","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/all.12142","article-title":"Skin test concentrations for systemically administered drugs -- an ENDA\/EAACI Drug Allergy Interest Group position paper","volume":"68","author":"Brockow","year":"2013","journal-title":"Allergy"},{"key":"R17-20250801","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/EJA.0000000000001765","article-title":"Neuromuscular blocking agent induced hypersensitivity reaction exploration: an update","volume":"40","author":"Dejoux","year":"2022","journal-title":"Eur J Anaesthesiol"},{"key":"R18-20250801","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.bja.2019.01.002","article-title":"In vitro diagnostic tests for perioperative hypersensitivity, a narrative review: potential, limitations, and perspectives","volume":"123","author":"Takazawa","year":"2019","journal-title":"Br J Anaesth"},{"key":"R19-20250801","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/aas.12855","article-title":"Anaesthetic hypersensitivity reactions in France between 2011 and 2012: the 10th GERAP epidemiologic survey","volume":"61","author":"Tacquard","year":"2017","journal-title":"Acta Anaesthesiol Scand"},{"key":"R20-20250801","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/all.13820","article-title":"An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions","volume":"74","author":"Garvey","year":"2019","journal-title":"Allergy"},{"key":"R21-20250801","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/all.13456","article-title":"Neuromuscular blocking agents induced anaphylaxis: results and trends of a French pharmacovigilance survey from 2000 to 2012","volume":"73","author":"Petitpain","year":"2018","journal-title":"Allergy"},{"key":"R22-20250801","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/j.bja.2019.03.038","article-title":"Awake intravenous provocation with small doses of neuromuscular blocking agent in patients with suspected allergy: experiences from the Dutch Perioperative Allergy Centre","volume":"123","author":"van Cuilenborg","year":"2019","journal-title":"Br J Anaesth"},{"key":"R23-20250801","doi-asserted-by":"crossref","first-page":"101","DOI":"10.18176\/jiaci.0402","article-title":"Drug challenge tests with general anesthetics: predictive value of skin tests","volume":"30","author":"Tornero Molina","year":"2020","journal-title":"J Invest Allergol Clin Immunol"},{"key":"R24-20250801","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2222.2009.03404.x","article-title":"BSACI guidelines for the investigation of suspected anaphylaxis during general anaesthesia","volume":"40","author":"Ewan","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"R25-20250801","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/ACI.0000000000000543","article-title":"Drug provocation testing: risk stratification is key","volume":"19","author":"Garvey","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R27-20250801","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jaci.2016.02.015","article-title":"Human IgE-independent systemic anaphylaxis","volume":"137","author":"Finkelman","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"R28-20250801","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/EJA.0000000000001769","article-title":"Peri-operative management of neuromuscular blockade: a guideline from the European Society of Anaesthesiology and Intensive Care","volume":"40","author":"Fuchs-Buder","year":"2023","journal-title":"Eur J Anaesthesiol"}],"container-title":["European Journal of Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/EJA.0000000000002033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T16:00:47Z","timestamp":1754064047000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/EJA.0000000000002033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/eja.0000000000002033","relation":{},"ISSN":["0265-0215","1365-2346"],"issn-type":[{"value":"0265-0215","type":"print"},{"value":"1365-2346","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]}}}